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15.1  Radionuclide Imaging of Bone 
 It was the development of the cyclotron by Ernest Lawrence at Berkeley during the 
1930s that fi rst made radionuclides available in the quantity and variety to allow 
investigations of their medical use. Lawrence’s brother John, who was a physician, 
directed the fi rst clinical studies, which included an investigation by Charles Pecher 
of the treatment of metastatic bone disease with  89 Sr [ 1 ]. An important fi nding 
made at Berkeley was the discovery of  99m Tc in 1938 by Segrè and Seaborg in a 
sample of irradiated molybdenum [ 2 ]. But further developments had to await the 
end of the war. 
 Since calcium has no radioisotopes suitable for imaging, the next obvious ele-
ment to exploit was strontium. In 1959 Bauer and Wendeberg [ 3 ] described the fi rst 
clinical study with  85 Sr (Eγ = 514 keV; T 1/2 = 65 days), but its use was limited by the 
long half-life and consequent high radiation dose. In 1964 Charkes, Sklaroff and 
Bierly [ 4 ] described skeletal scintigraphy with  87m Sr (Eγ = 388 keV; T 1/2 = 2.8 h), a 
short half-life isomeric radionuclide conveniently available from a generator.  87m Sr 
was the bone agent used in Sheffi eld where one of us (GB) started work in 1972. Its 
disadvantage was the high renal tubular reabsorption of strontium, which combined 
with the short half-life led to indistinct images with a high soft tissue background 
(Fig.  15.1 ).
 A much superior agent,  18 F-fl uoride, was described by Blau, Nagler and Bender 
in 1962 [ 5 ], but its use required an onsite cyclotron which was available in very few 
centres. By the early 1970s the situation was ripe for the introduction of  99m Tc 
labelled bone radiopharmaceuticals. 
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 Fig. 15.1  Colour ribbon 
printout of an  87m Sr bone 
scan performed on a 
rectilinear scanner 
(Reproduced with 
permission from Kemp 
et al. [ 20 ]) 
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 Interest in  99m Tc for Nuclear Medicine imaging began in the early 1960s follow-
ing the development of the  99m Tc generator by Tucker and Greene at the Brookhaven 
laboratory [ 6 ]. The fi rst technetium labelled bone agent,  99m Tc-polyphosphate, was 
described by Subramanian and McAfee [ 7 ] in 1971 (Fig.  15.2 ), and so radical was 
the improvement in image quality that by 1973  87m Sr had fallen out of use.
 In 1975 Subramanian described a superior agent,  99m Tc-methylene diphospho-
nate [ 8 ], and with the introduction of the wide-fi eld-of-view gamma camera and the 
replacement of spot views with whole-body scans the Nuclear Medicine bone scan 
took its modern form. 
 Recent years have seen a further change in the choice of optimum tracer as the 
wider availability of PET scanners has brought renewed interest in  18 F-fl uoride.  18 F 
 Fig. 15.2  Black and white fi lm scintiscan from a rectilinear scanner showing a  99m Tc- 
polyphosphate bone scan in a patient with no abnormalities (Reproduced with permission from 
Redman and Turley [ 21 ]) 
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is superior to  99m Tc-MDP for skeletal imaging because of its higher plasma clear-
ance to bone and absence of protein binding, both factors that lead to improved bone 
to soft tissue uptake. In addition PET is a superior imaging technique with higher 
spatial resolution and sensitivity compared with the gamma camera. The  99m Tc- 
MDP bone scan is an old and trusted friend that continues to perform with some 
distinction, but it is apparent that we can do signifi cantly better with  18 F. As PET 
scanners become more widely available there appears to be a compelling case for 
the introduction of  18 F-fl uoride as the preferred agent [ 9 ]. 
15.2  Quantitation of Bone Tracer Kinetics 
 There is a large early literature describing non-imaging studies of bone tracer 
kinetics using nuclides such as  45 Ca (T 1/2 = 163 days),  47 Ca (T 1/2 = 4.5 days) and  85 Sr 
(T 1/2 = 65 days). Imaging studies using short half-life tracers such as  99m Tc-MDP 
and  18 F-fl uoride provide more restricted information, but have the advantage of 
allowing regional as well as whole skeleton measurements. Perhaps the most 
widely known bone quantitation method using an imaging tracer is the 24-h  99m Tc-
MDP whole- body retention test described by Fogelman in the late 1970s while 
working at the Glasgow Royal Infi rmary [ 10 ]. In this test the patient is injected 
with a tracer amount (~1 MBq) of  99m Tc-MDP and has a head-to-foot measurement 
in a shadow shield whole-body counter. The measurement is repeated 24 h later 
and, on the assumption the tracer is either cleared to bone or excreted through the 
kidneys, the counts are corrected for background and radioactive decay and the 
retention of  99m Tc-MDP calculated. With the lack today of whole-body counter 
facilities, Brenner described a gamma camera measurement of whole-skeleton 
uptake based on whole-body scans acquired at 3 min and 6 h after injection [ 11 ]. 
By drawing a large region of interest over the adductor muscles the percentage of 
tracer still in soft tissue at 6 h is inferred and subtracted from the whole body reten-
tion to estimate the amount in bone. 
 A new method of using gamma camera scans to perform whole-skeleton and 
regional measurements of  99m Tc-MDP bone plasma clearance (analogous to the mea-
surement of renal function using GFR) was developed by Amelia Moore and col-
leagues at Guy’s Hospital [ 12 ]. Fast (~10 min) anterior and posterior whole-body scans 
are performed at 10 min, 1, 2, 3 and 4 h after injection, and blood samples taken at 5, 
20, 60, 120, 180 and 240 min. The latter are centrifuged by ultrafi ltration to determine 
the plasma concentration of free (non-protein bound)  99m Tc-MDP and the Patlak 
method used to determine whole-skeleton and regional (skull, spine, pelvis, arms, legs) 
bone plasma clearance. The method was used by Moore to investigate the effect of 
teriparatide on the bone scan in postmenopausal women treated for osteoporosis [ 13 ]. 
 Just as PET imaging with  18 F-fl uoride is superior to the  99m Tc-MDP gamma camera 
scan, the same is true for bone quantitation. Hawkins et al. [ 14 ] described a method of 
measuring  18 F bone plasma clearance in the lumbar spine (units: mL min −1 mL −1 ) by 
applying compartmental modelling to a 60-min dynamic PET scan with arterial sam-
pling of the plasma curve. The method was simplifi ed by Michelle Frost and 
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colleagues at Guy’s Hospital [ 15 ] so that from a series of venous blood samples and 
bed positions regional plasma clearance could be measured across the entire skeleton 
with a single injection of tracer. With the ability of  18 F PET scans to make measure-
ments at the hip, the most important fracture site, we believe this is the best method 
for studying the effect of osteoporosis treatments on regional bone metabolism. 
15.3  Bone Densitometry 
 The fi rst bone densitometer based on photon absorptiometry was described by 
Cameron and Sorenson in 1963 [ 16 ] and used the 27 keV radiation from a  125 I 
source to measure bone mineral content in the radius, a method known as single 
photon absorptiometry (SPA). Because the beam contained photons with just a sin-
gle energy it was necessary to place the patient’s forearm in a water bath to simulate 
a constant thickness of soft tissue across the wrist. 
 During the 1970s Medical Physics groups at the University of Wisconsin and 
other centres pioneered the development of dual photon absorptiometry (DPA) 
using a rectilinear scanning device with a  153 Gd source with emissions at 44 and 
100 keV [ 17 ]. Unlike SPA, these devices were able to scan the spine and hip. By 
the early 1980s several companies were manufacturing DPA scanners and in 
1982 Frans Verlaan, founder of Vertec Scientifi c, organised a conference in 
London for those interested in the new technology that was attended by many 
from the Nuclear Medicine community. In some UK centres medical physicists 
such as Victor Poll in Southampton built their own systems from old rectilinear 
scanners. Because of the use of a radioactive source, the DPA devices were 
largely confi ned to Nuclear Medicine Departments with experience in the safe 
handling of radionuclides. 
 The limitation of DPA was that it is impossible to contain suffi cient radioactivity in 
a small enough volume to achieve both the necessary count rate and adequate spatial 
resolution. In 1988 in the recently opened Guy’s Osteoporosis Unit patient appoint-
ment times for the Novo BMC-LAB 22a DPA system were 1 h long, as it took 30 min 
to scan and analyse the spine, and a similar time for the hip (Fig.  15.3a, b ).
 In the same year bone densitometry was revolutionised when Jay Stein, founder 
of Hologic, replaced the  153 Gd source with an X-ray tube and produced the fi rst dual-
energy X-ray absorptiometry (DXA) system. This provided an improvement in scan 
quality for bone densitometry just as radical as  99m Tc-MDP had for the radionuclide 
bone scan a decade earlier. Overnight the market for DPA systems was dead! 
 With a rapidly growing number of centres offering a DXA service it was neces-
sary to devise clearer ways of reporting scans. In 1994 a group of physicians led by 
John Kanis recommended that DXA scans should be interpreted using T-scores 
defi ned as the BMD measurement expressed in standard deviation units relative to 
a population of healthy young adults, with osteoporosis defi ned as a T-score of less 
than −2.5 at the spine, hip or forearm [ 18 ]. This simple defi nition caught the imagi-
nation of clinicians and ever since the T-score has been a cornerstone of DXA scan 
reporting. But it ignores the fact that fracture risk increases progressively with 
15 Bone Radionuclide Imaging, Quantitation and Bone Densitometry
116
diminishing BMD and does not take into account factors such as age and previous 
fractures in evaluating risk. In 2008 a collaboration under John Kanis placed the 
interpretation of DXA scans on a more secure footing by launching the FRAX web-
site [ 19 ] where a clinician can enter details of a patient’s hip T-score and clinical 
risk factors and obtain an estimate of their 10-year risk of fracture. 
 Fig. 15.3  ( a ) A Novo BMC-LAB 22a DPA scanner as used in the mid-1980s. ( b ) A lumbar spine 
DPA scan being analysed on a Novo BMC-LAB 22a system. Note the facility for the line-by-line 
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 Open Access This chapter is distributed under the terms of the Creative Commons Attribution-
Noncommercial 2.5 License ( http://creativecommons.org/licenses/by-nc/2.5/ ) which permits any 
noncommercial use, distribution, and reproduction in any medium, provided the original author(s) 
and source are credited. 
 The images or other third party material in this chapter are included in the work’s Creative 
Commons license, unless indicated otherwise in the credit line; if such material is not included in 
the work’s Creative Commons license and the respective action is not permitted by statutory regu-
lation, users will need to obtain permission from the license holder to duplicate, adapt or reproduce 
the material. 
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 Glen  M.  Blake  I was born in Walthamstow in East London and was fortunate to 
benefi t from the 11-Plus exam, going to Chigwell School in Essex. I won an open 
scholarship to study Physics at Oxford and came out with the top fi rst in my year 
group. After that I did a PhD in the Radio Astronomy group at the Cavendish 
Laboratory under Martin Ryle. My interest in Medical Physics developed from a 
fellow research student, Lawrence Oldfi eld, who had just returned from a year 
working in Canada in radiotherapy. My fi rst post in the NHS was in Sheffi eld where 
the Medical Physics Department was led by Harold Miller. Harold had been a stu-
dent of James Chadwick in 1932, the year that Chadwick discovered the neutron. I 
worked in the Isotope Unit at the Sheffi eld Royal Infi rmary, and later at the 
Hallamshire Hospital when it opened in 1978. There I worked with John Kanis on a 
grant proposal to purchase one of the early DPA bone density scanners for research 
projects in Sheffi eld. In 1984 I moved to the Nuclear Medicine Department at 
Southampton under Duncan Ackery where I widened my experience and was 
involved with projects that included the use of  89 Sr to treat metastatic bone disease. 
In 1989 I moved to the Nuclear Medicine Department at Guy’s Hospital under Ignac 
Fogelman. Here I had the opportunity to take up bone densitometry again in the 
recently opened Osteoporosis Unit. At Guy’s I became more heavily involved with 
teaching and supervising research students, and in 2003 I moved from the NHS to 
work for King’s College London, becoming Professor of Osteoporosis in 2012. 
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